James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Can Singles Day Be the Shot in the Arm BABA Needs?

Alibaba stock still merits lots of good questions, but there's no denying the positive impact this giant shopping event could have on BABA.

Why Juniper Networks, Inc. (JNPR), Macy’s, Inc. (M) and Priceline Group Inc (PCLN) Are 3 of Today’s Worst Stocks

Juniper Networks (JNPR), Macy's (M) and Priceline Group (PCLN) led the bearish charge on Monday, though for understandable reasons.

The iPad Pro Launch Doesn’t Make Apple Stock Any More Investment-Worthy

A few businesses may fall in love with the upcoming iPad Pro, but AAPL investors need not be enthusiastic about the impact it could have on Apple stock.

Why Freeport-McMoRan Inc (FCX), Tripadvisor Inc (TRIP) and Dr.Reddy’s Laboratories Ltd (RDY) Are 3 of Today’s Worst Stocks

Freeport-McMoRan (FCX), Tripadvisor (TRIP) and Dr.Reddy's Laboratories (RDY) couldn't end the trading week soon enough.

SHAK Stock Has Been Taken Off Its Pedestal

SHAK stock is alarmingly stagnant following its solid Q3 earnings report. Here's why investors might be concerned.